Pedro Estrela is Professor of Biosensors and Bioelectronics at the Department of Electronic & Electrical Engineering and Director of the Centre for Bioengineering & Biomedical Technologies (CBio) at the University of Bath. He has a background in Physics (degree and Masters from the University of Lisbon, PhD from the University of Amsterdam) and started working in the field of biosensors in 2000 (University of Cambridge until 2008 and University of Bath since 2008). He is Co-Director of the Centre of Excellence in Water-Based Early-Warning Systems for Health Protection (CWBE), Co-Director of the NERC Centre for Doctoral Training in Real-Time Digital Water-Based Systems for Environmental Health Protection (Red-ALERT CDT), and member of the Steering Committee of the Centre for Therapeutic Innovation. Prof. Estrela’s research focuses on the development of label-free electrical, electrochemical and plasmonic biosensors and lab-on-chip devices for a wide range of applications such as medical diagnosis, prognosis and monitoring as well as water/wastewater monitoring. He has over 170 peer-reviewed publications (h-index 49). He is an Associate Editor for the journals Biosensors & Bioelectronics, Sensors, Frontiers in Sensors and Advanced Devices & Instrumentation and Specialty Chief Editor in Frontiers in Lab on a Chip Technologies.
Dr Susan Pang is a Science Leader in Innovation at the National Measurement Laboratory at LGC. She has over 20 years’ experience in Biochemistry, Molecular and Cell Biology, covering a broad range of analytical technologies and implementing measurement science. She primarily specialises in immunoassay development and devises novel approaches to assay development using open platform technologies to improve sensitivity, overcome matrix interference and enhance assay turnaround. She provides consultancy for immunoassay construction with developmental biosensor technologies and offers robust cross-platform evaluations. She has recently joined the IUPAC wearable sensors working group to input on general requirements for validation and metrology.
Richard Luxton, Director of the Institute of Bio-Sensing Technology studied clinical chemistry in the National Health Service for thirteen years at the Bristol Royal Infirmary before moving to the Institute of Neurology in London to study for a PhD in neuro-immunology.
At the University of the West of England he focused his research in the area of developing new rapid detection technologies for point of care diagnostics for use in primary care settings. In 2008 he launched the Institute of Bio-Sensing Technology, which seeks to develop new collaborations between industry and academia through inter-disciplinary research. In 2012 he was instrumental in launching Medilink South West, a networking organisation for the Health and Life Science sector in the South West of England and is currently the company chairman.
In 2014, together with Professor Janice Kiely, he launched a European funded Business Technology Centre to develop cell monitoring technology and supporting companies develop their products by enabling access to cutting edge technologies. From this a new Health Technology Hub was opened in 2018 at the University of the West of England which has cutting edge laboratories and workshops that support research and development of bio-sensing technology, health-tech and devices for assisted living. He currently is the academic lead of the South West NHS Centre of Digital Excellence at the University of the West of England, a NHS funded programme launched in 2024 to evaluate digital technologies used in the primary care sector.
He has led many large multi-partner projects to develop new technology for the rapid detection of analytes at the point of test. Richard is the founder and Conference Chair of the successful International Conference for Bio-sensing Technology and Editor in Chief for the Journal Sensor and Biosensor Research.
Damion is our CAMS MSI co-Chair and a LGC Professor in Measurement Science for Health at the University of Strathclyde, leading the Centre for Advanced Measurement and Health Translation. His research focuses on electrochemical sensing, analytical chemistry, and device fabrication, aiming to develop improved diagnostic tests for conditions such as drug-resistant bacterial infections, COVID-19, sepsis, cancer, and epilepsy.
He is the founding Director and Chief Scientific Officer of Aureum Diagnostics, a company developing low-cost electrochemical diagnostic assays, and co-founder and Chief Technology Officer of Microplate Dx, which specializes in selecting the best antibiotic treatments for infections.
Damion has received multiple accolades, including Academic Entrepreneur of the Year (2024) at the Praxis Auril Knowledge Exchange Awards.
